↓ Skip to main content

Dove Medical Press

Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19

Overview of attention for article published in Drug Design, Development and Therapy, July 2020
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

patent
2 patents
peer_reviews
1 peer review site
wikipedia
2 Wikipedia pages

Readers on

mendeley
64 Mendeley
Title
Plasmapheresis, Anti-ACE2 and Anti-FcγRII Monoclonal Antibodies: A Possible Treatment for Severe Cases of COVID-19
Published in
Drug Design, Development and Therapy, July 2020
DOI 10.2147/dddt.s262491
Pubmed ID
Authors

Amin Sedokani, Sadegh Feizollahzadeh

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 64 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 64 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 19%
Student > Bachelor 7 11%
Student > Doctoral Student 6 9%
Student > Ph. D. Student 6 9%
Other 5 8%
Other 7 11%
Unknown 21 33%
Readers by discipline Count As %
Medicine and Dentistry 17 27%
Biochemistry, Genetics and Molecular Biology 5 8%
Agricultural and Biological Sciences 3 5%
Immunology and Microbiology 3 5%
Nursing and Health Professions 2 3%
Other 14 22%
Unknown 20 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2022.
All research outputs
#4,839,541
of 25,387,668 outputs
Outputs from Drug Design, Development and Therapy
#304
of 2,268 outputs
Outputs of similar age
#116,973
of 432,368 outputs
Outputs of similar age from Drug Design, Development and Therapy
#9
of 48 outputs
Altmetric has tracked 25,387,668 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 432,368 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 48 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.